How to buy Neoleukin Therapeutics stock - 07 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Neoleukin Therapeutics stock

Own Neoleukin Therapeutics stock in just a few minutes.

Fact checked

Neoleukin Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Neoleukin Therapeutics shares (NLTX) are listed on the NASDAQ and all prices are listed in US Dollars. Neoleukin Therapeutics employs 65 staff and has a market cap (total outstanding shares value) of USD$498.2 million.

How to buy shares in Neoleukin Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Neoleukin Therapeutics. Find the stock by name or ticker symbol: NLTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neoleukin Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neoleukin Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Neoleukin Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Neoleukin Therapeutics share price

Use our graph to track the performance of NLTX stocks over time.

Neoleukin Therapeutics shares at a glance

Information last updated 2021-03-02.
52-week rangeUSD$5.81 - USD$18.13
50-day moving average USD$13.114
200-day moving average USD$12.5906
Wall St. target priceUSD$22.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.938

Buy Neoleukin Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neoleukin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neoleukin Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -15.94%
Return on equity TTM -21.51%
Profit margin 0%
Book value $2.376
Market capitalisation USD$498.2 million

TTM: trailing 12 months

Shorting Neoleukin Therapeutics shares

There are currently 3.2 million Neoleukin Therapeutics shares held short by investors – that's known as Neoleukin Therapeutics's "short interest". This figure is 7.7% up from 3.0 million last month.

There are a few different ways that this level of interest in shorting Neoleukin Therapeutics shares can be evaluated.

Neoleukin Therapeutics's "short interest ratio" (SIR)

Neoleukin Therapeutics's "short interest ratio" (SIR) is the quantity of Neoleukin Therapeutics shares currently shorted divided by the average quantity of Neoleukin Therapeutics shares traded daily (recently around 244580.15209125). Neoleukin Therapeutics's SIR currently stands at 13.15. In other words for every 100,000 Neoleukin Therapeutics shares traded daily on the market, roughly 13150 shares are currently held short.

However Neoleukin Therapeutics's short interest can also be evaluated against the total number of Neoleukin Therapeutics shares, or, against the total number of tradable Neoleukin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neoleukin Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Neoleukin Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0898% of the tradable shares (for every 100,000 tradable Neoleukin Therapeutics shares, roughly 90 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Neoleukin Therapeutics.

Find out more about how you can short Neoleukin Therapeutics stock.

Neoleukin Therapeutics share dividends

We're not expecting Neoleukin Therapeutics to pay a dividend over the next 12 months.

Neoleukin Therapeutics share price volatility

Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $5.81 up to $18.13. A popular way to gauge a stock's volatility is its "beta".

NLTX.US volatility(beta: 1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neoleukin Therapeutics's is 1.0043. This would suggest that Neoleukin Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Neoleukin Therapeutics overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site